Teplizumab 2025: Everything To Know About T1D Breakthrough
Discover how Teplizumab delays type 1 diabetes progression, offering hope for stage 2 patients aged 8 and older.
Teplizumab, marketed as Tzield, represents a revolutionary advancement in type 1 diabetes management as the first disease-modifying therapy approved to delay progression from stage 2 to stage 3 type 1 diabetes (T1D) in patients aged 8 years and older.
What is teplizumab?
Teplizumab-mzwv is an intravenous monoclonal antibody specifically designed to intervene in the autoimmune process of type 1 diabetes. Unlike traditional treatments that manage symptoms after diagnosis, teplizumab targets the underlying immune attack on pancreatic beta cells, which produce insulin.
Type 1 diabetes develops in stages: Stage 1 involves the presence of multiple autoantibodies with normal blood sugar; stage 2 features dysglycemia (abnormal blood sugar) but preserved insulin production; and stage 3 requires insulin therapy due to significant beta cell loss. Teplizumab is indicated for stage 2 patients who test positive for two or more T1D-related autoantibodies and exhibit abnormal oral glucose tolerance test results, excluding those with type 2 diabetes.
Approved by the FDA in November 2022, this therapy provides a median delay of about two to three years before clinical diagnosis of stage 3 T1D, offering precious time for patients to maintain natural insulin production.
How does teplizumab work?
Teplizumab functions as an anti-CD3 monoclonal antibody that binds to CD3 molecules on the surface of T lymphocytes, including CD4+ and CD8+ cells responsible for destroying insulin-producing beta cells in the pancreas.
By partially activating these autoreactive T cells through agonistic signaling, teplizumab modulates the immune response without fully depleting T cells. It deactivates the harmful T cells specifically involved in beta cell destruction while sparing those needed for fighting infections and maintaining overall immune function. This selective action helps preserve beta cells longer.
Clinical trials, such as the pivotal TrialNet study (TN-10), demonstrated that a single 14-day course extended the median time to stage 3 T1D from 24.4 months in the placebo group to 48.4 months in the teplizumab group. Notably, 43% of treated participants avoided progression compared to 72% in controls.
Who can have teplizumab?
Eligibility for teplizumab is strictly defined for individuals aged 8 years and older with stage 2 type 1 diabetes. Key criteria include:
- Positive for at least two type 1 diabetes autoantibodies (e.g., GAD, IA-2, ZnT8, or insulin autoantibodies).
- Dysglycemia confirmed by an abnormal oral glucose tolerance test (OGTT), such as 2-hour glucose between 140-199 mg/dL or fasting glucose 100-125 mg/dL.
- No diagnosis of type 2 diabetes or other conditions explaining the abnormalities.
- Family history or screening identification of high risk, often through programs like TrialNet.
Screening is crucial and typically involves blood tests for autoantibodies and OGTT. Increased awareness post-approval has boosted screening rates, aiding early detection of at-risk individuals and preventing complications like diabetic ketoacidosis.
Having teplizumab
Teplizumab is administered as a 14-day course of intravenous (IV) infusions, given once daily in a clinical setting under medical supervision. Dosing escalates gradually to minimize side effects:
| Day | Dose (mg) | Infusion Duration |
|---|---|---|
| Days 1-3 | 0.1 – 0.3 – 0.67 | 30 minutes |
| Days 4-7 | 1 – 2 – 4 – 4 | 60 minutes |
| Days 8-14 | 9 mg daily | 120 minutes |
Patients must be monitored for at least two hours post-infusion on day 14 due to potential cytokine release syndrome (CRS). No premedication is required, but facilities must have emergency equipment available.
Treatment is outpatient after initial doses, but patients should avoid live vaccines for 45 days before and 3 months after therapy. Close monitoring of blood sugars is essential during and post-treatment.
Side effects of teplizumab
Common side effects are mostly mild to moderate and resolve within days. They stem from immune modulation:
- Cytokine release syndrome (CRS): Rash (70%), fever/chills (48%), nausea/vomiting (45%), headache (38%). Peaks early, managed supportively.
- Lymphopenia (temporary drop in lymphocytes, 90% of patients, resolves in weeks).
- Infections (upper respiratory, 80%; serious infections rare).
- Injection site reactions, fatigue, abdominal pain.
Serious risks include severe CRS, hypersensitivity, and potential increased autoantibody titers. Long-term data show no increased malignancy or persistent immunosuppression. Patients with active infections or recent live vaccines are contraindicated.
Effectiveness of teplizumab
Landmark trials confirm teplizumab’s efficacy. In TN-10 (76 participants, ages 8+), median delay was ~2 years; 50% of treated patients remained stage 2 at 5 years.
Another trial (112 screened) showed significant hazard reduction (HR 0.44). Benefits are greater in those with lower baseline glucose or fewer autoantibodies. It sets a foundation for combination therapies to extend delays further.
Real-world use has increased screening, benefiting public health by identifying at-risk individuals early.
Accessing teplizumab
In the US, Tzield is available via Progenity’s HUB services, including a Risk Evaluation and Mitigation Strategy (REMS) program. Providers must certify, and infusions occur at authorized centers.
Insurance coverage varies; patient assistance programs exist. In the UK/EU, access is limited pending approvals—check NICE or EMA. TrialNet and similar programs offer screening.
Consult endocrinologists or diabetes centers for screening and eligibility assessment.
Frequently asked questions
Who is eligible for teplizumab?
Patients 8+ with stage 2 T1D: ≥2 autoantibodies, dysglycemia on OGTT, no T2D.
How long does one course last?
14 daily IV infusions; effects delay progression median 2-3 years.
Is teplizumab a cure?
No, it delays stage 3 but does not halt or reverse T1D.
Can it be repeated?
Not yet approved for retreatment; studies ongoing.
What are the main side effects?
CRS symptoms like rash, fever; mostly transient.
Future directions
Teplizumab paves the way for expanded disease-modifying therapies. Research explores combinations, earlier intervention, and predictors of response to prolong beta cell preservation.
References
- What is Teplizumab? Why You Should Know This Diabetes Drug — CU Anschutz Medical Campus. 2023-05-01. https://news.cuanschutz.edu/medicine/teplizumab-diabetes-drug-treatment
- Teplizumab: a promising intervention for delaying type 1 diabetes — Frontiers in Endocrinology. 2025-03-27. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1533748/full
- Teplizumab is the first drug to delay the diagnosis of T1D for a median of two years — TrialNet. 2023-06-20. https://www.trialnet.org/events-news/blog/teplizumab-first-drug-delay-diagnosis-t1d-median-two-years
- Teplizumab-mzwv (intravenous route) – Side effects & uses — Mayo Clinic. 2025-01-15. https://www.mayoclinic.org/drugs-supplements/teplizumab-mzwv-intravenous-route/description/drg-20542447
- Tzield (teplizumab): First-in-Class Drug Therapy That Delays Onset — ACCP. 2023-02-10. https://www.accp.com/stunet/newsletter.aspx?art=154
- TZIELD.com | For US Consumers — TZIELD (Progenity). 2025-12-01. https://www.tzield.com
- Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab — Diabetes Care (ADA). 2025-10-01. https://diabetesjournals.org/care/article/doi/10.2337/dci25-0066/163760/Toward-Disease-Modifying-Therapies-in-Type-1
Similar Articles
Read full bio of medha deb
